Abstract
Although recent data suggest that pimozide has effects at other neurotransmitter receptor sites, it is one of the more specific neuroleptics in its effects on dopamine receptors. We report that in manic patients pimozide produces substantial clinical improvement with a magnitude and time course similar to that observed with the more routinely used phenothiazines chlorpromazine and thioridazine. Pimozide did not significantly increase probenecid-induced accumulations of the dopamine metabolite homovanillic acid (HVA) compared to pretreatment values. Higher HVA values were observed in manic than in nonmanic patients, however. These clinical and biochemical data add to a growing body of indirect evidence that a dopaminergic alteration may be associated with some components of the manic syndrome.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Andén, N. E., Butcher, S. G., Corrodi, H., Fuxe, K., Ungerstedt, U.: Receptor activity of turnover of dopamine of noradrenaline after neuroleptics. Eur. J. Pharmacol. 11, 303–314 (1970)
Baudry, M., Martres, M. P., Schwartz, J. C.: In vivo binding of 3H-pimozide in mouse striatum: Effects of dopamine agonists and antagonists. Life Sci. 21, 1163–1170 (1977a)
Baudry, M., Costentin, J., Marcais, H., Martres, M. P., Protais, P., Schwartz, J. C.: Decreased responsiveness to low doses of apomorphine after dopamine agonists and the possible involvement of hyposensitivity of dopamine “autoreceptors”. Neurosci. Letters 4, 203–207 (1977b)
Blumberg, J. B., Taylor, R. E., Sulser, F.: Blockade by pimozide of a noradrenaline sensitive adenylate cyclase in the limbic forebrain: Possible role of limbic noradrenergic mechanisms in the mode of action of antipsychotics. J. Pharm. Pharmacol. 27, 125–128 (1975)
Bobon, D. P., Plomteux, G., Heusghem, C., Bobon, J.: Clinical toxicology and efficacy of pimozide. Int. Pharmacopsychiatry 4, 194–203 (1970)
Bowers, M. B.: Clinical indices of dopaminergic function. In: Catecholamines: Basic and clinical frontiers, p. 138
Bowers, M. B., Rozitis, A.: Brain homovanillic acid: Regional changes over time with antipsychotic drugs. Eur. J. Pharmacol. 39, 109–115 (1976)
Bunney, W. E., Jr., Hamburg, D. A.: Methods for reliable longitudinal observation of behavior. Arch. Gen. Psychiatry 9, 280–294 (1963)
Bunney, W. E., Jr., Brodie, H. K. H., Murphy, D. L., Goodwin, F. K.: Studies of alpha-methyl-para-tyrosine, l-dopa, and l-tryptophan in depression and mania. Am. J. Psychiatry 127, 872–881 (1971)
Carlsson, A.: Receptor-mediated control of dopamine metabolism. In: Pre- and postsynaptic receptors, E. Usdin, W. E. Bunney, Jr., eds., pp. 49–87. New York: Marcel Dekker 1975
Carlsson, A.: Antipsychotic drugs, neurotransmitters, and schizophrenia. Am. J. Psychiatry 135, 164–173 (1978)
Carlsson, A., Lindqvist, M.: Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and norepinephrine in mouse brain. Acta Pharmacol. Toxicol. (Kbh.) 20, 140–144 (1963)
Claghorn, J. L.: A double-blind comparison of pimozide versus trifluoperozine in schizophrenic outpatients. Curr. Ther. Res. 16, 1005–1009 (1974)
Clement-Cormier, Y. C., Kebabian, J. W., Petzold, G., Greengard, P.: Dopamine-sensitive adenylate cyclase in mammalian brain: A possible site of action of antipsychotic drugs. Proc. Natl. Acad. Sci. USA 71, 1113–1117 (1974)
Corrodi, H., Fuxe, K., Schou, M.: The effect of prolonged lithium administration on cerebral monoamine neurons in the rat. Life Sci. 8, 643–651 (1969)
Corsini, G. U., Del Zompo, M., Manconi, S., Cianchetti, C., Mangoni, A., Gessa, G. L.: Sedative, hypnotic, and antipsychotic effects of low doses of apomorphine in man. In: Nonstriatal dopaminergic neurons: Advances biochemical psychopharmacology, vol. 16, E. Costa, G. L. Gessa, eds., pp. 645–648. New York: Raven 1977
Costall, B., Naylor, R. J.: Mesolimbic and extrapyramidal sites for the mediation of stereotyped behavior patterns and hyperactivity by amphetamine and apomorphine in the rat. In: Cocaine and other stimulants: Advances in behavioral biology, vol. 21, E. H. Ellinwood, M. M. Kilbey, eds., pp. 47–76. New York: Plenum 1977
Creese, I., Iversen, S. D.: The role of forebrain dopamine systems in amphetamine induced streotyped behavior in the rat. Psychopharmacologia 39, 345–357 (1974)
Creese, I., Burt, D. R., Snyder, S. H.: Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192, 481–483 (1967a)
Creese, I., Feinberg, A. P., Snyder, S. H.: Butyrophenone influences on the opiate receptor. Eur. J. Pharmacol. 36, 231–236 (1976b)
Creese, I., Prosser, T., Snyder, S. H.: Dopamine receptor binding: Specificity, localization and regulation by ions and guanyl nucleotides. Life Sci. 23, 495–500 (1978)
Denef, C., Follebouckt, J.-J.: Differential effects of dopamine antagonists on prolactin secretion from cultured rat pituitary cells. Life Sci. 23, 413–436 (1978)
Denijs, E. L., Vereecken, J. L. T. M.: Pimozide (Oral, R 6238) in residual schizophrenia. A clinical evaluation with long-term double-blind follow-up. Psychiatr. Neurol. Neurochir. 76, 47–59 (1973)
Ettenberg, A., Milner, P. M.: Effects of dopamine supersensitivity on lateral hypothalamic self-stimulation in rats. Pharmacol. Biochem. Behav. 7, 507–514 (1977)
Friedman, E., Gershon, S.: Effects of lithium on brain dopamine. Nature 243, 520–521 (1973)
Gallager, D. W., Aghajanian, G. K.: Effect of antipsychotic drugs on the firing of dorsal raphe cells. Role of adrenergic system. Eur. J. Pharmacol. 39, 341–355 (1976)
Gallager, D. W., Pert, A., Bunney, W. E., Jr.: Haloperidol-induced presynaptic dopamine supersensitivity is blocked by chronic lithium. Nature 273, 309–312 (1978)
Gerlach, J., Thorsen, K., Fog, R.: Extra-pyramidal reactions and amine metabolites in crebrospinal fluid during haloperidol and clozapine treatment of schizophrenic patients. Psychopharmacology 40, 341–350 (1975)
Gerner, R. H., Post, R. M., Bunney, W. E., Jr.: A dopaminergic mechanism in mania. Am. J. Psychiatry 133, 1177–1180 (1976)
Gianutsos, G., Thornburg, J. E., Moore, K. E.: Differential actions of dopamine agonists and antagonists on the gamma-butyrolactone-induced increase in mouse brain dopamine. Psychopharmacology 50, 225–229 (1976)
Glowinski, J.: Effects of neuroleptics on the nigroneostriatal and mesocortical dopaminergic systems. In: Biology of the major psychosis, D. X. Freedman, ed., pp. 233–246. New York: Raven 1975
Goldberg, J. B., Kurland, A. A.: Pimozide in the treatment of behavioral disorders of hospitalized adolescents. J. Clin. Pharmacol. 14, 134–139 (1974)
Goodwin, F. K., Brodie, H. K. H., Murphy, D. L., Bunney, W. E., Jr.: l-Dopa, catecholamines, and behavior: A clinical and biochemical study in depressed patients. Biol. Psychiatry 2, 341–366 (1970)
Goodwin, F. K., Post, R. M., Dunner, D. L., Gordon, E. K.: Cerebrospinal fluid amine metabolites in affective illness: The probenecid technique. Am J. Psychiatry 130, 73–79 (1973)
Gordon, E. K., Oliver, J.: 3-Methoxy-4-hydroxyphenylethylene glycol in human cerebrospinal fluid. Clin. Chim. Acta 35, 145–150 (1971)
Halaris, A. E., Freedman, D. X.: Psychotropic drugs and dopamine uptake inhibition. In: Biology of the major psychoses, D. X. Freedman, ed., pp. 247–258. New York: Raven 1975
Ho, A. K. S., Loh, H. H., Craves, F., Hitzeman, R. J., Gershon, S.: The effect of prolonged lithium treatment on the synthesis rate and turnover of monoamine in brain regions of rats. Eur. J. Pharmacol. 10, 72–78 (1970)
Horn, A. S., Phillipson, O. T.: A noradrenaline sensitive adenylate cyclase in the rat limbic forebrain: Preparation, properties and the effects of agonists, adrenolytics and neuroleptic drugs. Eur. J. Pharmacol. 37, 1–11 (1976)
Hyttel, J.: Effect of neuroleptics on the disappearance rate of 14C-labelled catecholamines formed from 14C-tyrosine in mouse brain. J. Pharm. Pharmacol. 26, 588–596 (1974)
Jacobs, B. L.: Effect of two dopamine receptor blockers on a serotonin-mediated behavioral syndrome in rats. Eur. J. Pharmacol. 27, 363–366 (1974)
Jimerson, D. C., Post, R. M., Skyler, J. Bunney, W. E., Jr.: Prolactin in cerebrospinal fluid and dopamine function in man. J. Pharm. Pharmacol. 28, 845–847 (1976)
Kebabian, J. W.: Multiple classes of dopamine receptors in mammalian central nervous system: The involvement of dopamine-sensitive adenylate cyclase. Life Sci. 23, 479–484 (1978)
Kelly, P. H., Iversen, S. D.: Selective 6-OHDA-induced destruction of mesolimbic dopamine neurons: Abolition of psychostimulant-induced locomotor activity in rats. Eur. J. Pharmacol. 40, 45–56 (1975)
Kolivakis, T., Hassan, A., Kingstone E: A double-blind comparison of pimozide and chlorpromazine in the maintenance care of chronic schizophrenic outpatients. Curr. Ther. Res. 16, 998–1004 (1974)
Ljungberg, T., Ungerstedt, U.: Different behavioral patterns induced by apomorphine: Evidence that the method of administration determines the behavioral response to the drug. Eur. J. Pharmacol. 46, 41–50 (1977)
Ljungberg, T., Ungerstedt, U.: Classification of neuroleptic drugs according to their ability to inhibit apomorphine-induced locomotion and gnawing: Evidence for two different mechanisms of action. Psychopharmacology 56, 239–347 (1978)
Modigh, K.: Long-term effects of electroconvulsive shock therapy on synthesis turnover and uptake of brain monoamines. Psychopharmacology 49, 179–185 (1976)
Molander, L., Randrup, A.: Effects of thymoleptics on behavior associated with changes in brain dopamine. Potentiation of dopa-induced gnawing of mice. Psychopharmacologia 45, 261–265 (1976a)
Molander, L., Randrup, A.: Effects of thymoleptics on behavior associated with changes in brain dopamine. Modification and potentiation of apomorphine-induced stimulation of mice. Psychopharmacology 49, 139–144 (1976b)
Murphy, D. L.: l-Dopa, behavioral activation, and psychopathology. In: Neurotransmitters, I. J. Kopin, ed., pp. 472–493. New York: Raven 1972
Murphy, D. L., Beigel, G., Weingartner, H., Bunney, W. E., Jr.: The quantitation of manic behavior. In: Psychological measurements in psychopharmacology: Modern problems in pharmacopsychiatry, vol. 7, P. Pichot, ed., pp. 203–220. Paris: Karger 1974
Papeschi, R., Randrup, A.: Effect of ECT on dopaminergic and noradrenergic mechanisms. Effect on dopamine and noradrenaline concentrations and turnovers. Psychopharmacologia 35, 159–168 (1974)
Pert, A., Rosenblatt, J. E., Sivit, C., Pert, C. B., Bunney, W. E., Jr.: Long-term treatment lithium prevents the development of dopamine receptor supersensitivity. Science 201, 171–173 (1978a)
Pert, C. B., Pert A., Rosenblatt, J. E., Tallman, J. F., Bunney, W. E., Jr.: Catecholamine receptor stabilization: a possible mode of lithium's antimanic action. In: Catecholamines: Basic and clinical frontiers, E. Usdin, I. J. Kopin, J. Barchas, eds., pp. 583–585. New York: Pergamon Press 1978
Pijnenburg, A., Honig, W., Vander-Heyden, J., Van Rossum, J.: Effects of chemical stimulation of the mesolimbic dopamine system upon locomotor activity. Eur. J. Pharmacol. 35, 45–58 (1976)
Post, R. M.: Cocaine psychoses: A continuum model. Am. J. Psychiatry 132, 225–231 (1975)
Post, R. M.: Frontiers in affective disorder research: New pharmacological agents and new methodologies. In: Psychopharmacology: A generation of progress, M. A. Lipton, A. DiMascio, K. F. Killam, eds., pp. 1323–1335. New York: Raven 1978
Post, R. M., Goodwin, F. K.: Time-dependent effects of phenothiazines on dopamine turnover in psychiatric patients. Science 190, 488–489 (1975)
Post, R. M., Gerner, R. H., Carman, J. S., Bunney, W. E., Jr.: Effects of low doses of a dopamine-receptor stimulator in mania. Lancet 1976 I, 203–204
Post, R. M., Gerner, R. H., Carman, J. S., Gillin, J. C., Jimerson, D. C., Goodwin, F. K., Bunney, W. E., Jr.: Effects of a dopamine agonist piribedil in depressed patients: Relationship of pretreatment HVA to antidepressant response. Arch. Gen. Psychiatry 35, 609–615 (1978)
Praag, H. M. van: The significance of dopamine for the mode of action of neuroleptics and the pathogenesis of schizophrenia. Br. J. Psychiatry 130, 463–474 (1977a)
Praag, H. M. van: Significance of biochemical parameters in the diagnosis, treatment, and prevention of depressive disorders. Biol. Psychiatry 12, 101–131 (1977b)
Praag, H. M. van, Korf, J.: Serotonin metabolism in depression: Clinical application of the probenecid test. Int. Pharmacopsychiatry 9, 35–51 (1974)
Puech, A. J., Simon, P., Boissier, J. R.: Benzamides and classical neuroleptics: Comparison of their actions using six apomorphine-induced effects. Eur. J. Pharmacol. 50, 291–300 (1978)
Randrup, A., Braestrup, C.: Uptake inhibition of biogenic amines by newer antidepressant drugs: Relevance to the dopamine hypothesis of depression. Psychopharmacology 53, 309–314 (1977)
Randrup, A., Munkvad, I., Fog, R., Gerlach, J., Molander, L., Kjellberg, B., Scheel-Kruger, J.: Mania, depression, and brain dopamine. Curr. Dev. Psychopharmacol. 2, 205–248 (1975)
Riding, J., Munro, A.: Pimozide in the treatment of monosymptomatic hypochondriacal psychosis. Acta Psychiatr. Scand. 52, 23–30 (1975)
Rossum, J. M. van: Mode of action of psychomotor stimulant drugs. Int. Rev. Neurobiol. 12, 307–383 (1970)
Sack, R. L., Goodwin, F. K.: Inhibition of dopamine β-hydroxylase in manic patients. Arch. Gen. Psychiatry 31, 649–654 (1974)
Sawaya, M. C. B., Dolphin, A., Jenner, P., Marsden, C. D., Meldrum, B. S.: Noradrenaline-sensitive adenylate cyclase in slices of mouse limbic forebrain: Characterisation and effect of dopaminergic agonists. Biochem. Pharmacol. 26, 1877–1884 (1977)
Scatton, B., Glowinski, J., Julou, L.: Dopamine metabolism in the mesolimbic and mesocortical dopaminergic systems after single or repeated administrations of neuroleptics. Brain Res. 109, 184–189 (1976)
Scatton, B., Boireau, A., Garret, C., Glowinski, J., Julou, L.: Action of the palmitic ester of pipotiazine on dopamine metabolism in the nigrostriatal, mesolimbic and mesocortical systems. Naunyn Schmiedebergs Arch. Pharmacol. 296, 169–175 (1977)
Scheel-Kruger, J., Braestrup, C., Nielson, M., Golembiowska, K., Mogilnicka, E.: Cocaine: Discussion on the role of dopamine in the biochemical mechanism of action. In: Cocaine and other stimulants: Advances in behavioral biology, vol. 21, E. H. Ellinwood, M. M. Kilbey, eds., pp. 373–407. New York: Plenum 1977
Sedvall, G., Bjerkenstedt, L., Lindstrom, L., Wode-Helgodt, B.: Clinical assessment of dopamine receptor blockade. Life Sci. 23, 425–430 (1978)
Sedvall, G., Fyro, B., Nyback, H., Wiesel, F. A., Wode-Helgodt, B.: Mass fragmentometric determination of homovanillic acid in lumbar cerebrospinal fluid of chizophrenic patients during treatment with antipsychotic drugs. J. Psychiatr. Res. 11, 75–80 (1974)
Seeman, P., Lee, T., Chau-Wong, M., Wong, K.: Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261, 717–719 (1976)
Seeman, P., Tedesco, J. L., Lee, T., Chau-Wong, M., Muller, P., Bowles, J., Withaker, P. M., McManus, C., Tittler, M., Weinreich, P., Friend, W. C., Brown, G. M.: Dopamine receptors in the central nervous system. Fed. Proc. 37, 130–136 (1978)
Segal, D. S., Callaghan, M., Mandell, A. J.: Alterations in behavior and catecholamine biosynthesis induced by lithium. Nature 254, 58–59 (1975)
Shopsin, B., Gershon, S.: Dopamine receptor stimulation in the treatment of depression: Piribedil (ET-495). Neuropsychobiology 4, 1–14 (1978)
Snyder, S. H., Creese, I., Burt, D. R.: The brain's dopamine receptor: Labeling with 3H-dopamine and 3H-haloperidol. Psychopharmacol. Commun. 1, 663–673 (1975)
Snyder, S. H., Banerjee, S. P., Yamamura, H. I., Greenberg, D.: Drugs, neurotransmitters, and schizophrenia. Science 184, 1243–1254 (1974)
Spitzer, R. L., Endicott, J., Robins, E.: Clinical criteria for psychiatric diagnosis and DSM-III. Am. J. Psychiatry 132, 1186–1192 (1975)
Sternberg, D. E., van Kammen, D. P., Lake, R. C., Ballenger, J. C., Bunney, W. E., Jr.: Cerebrospinal fluid norepinephrine in schizophrenia. Sci. Proc. Am. Psychiatr. Assoc. 132, 344 (1979)
Strombom, U.: Effects of low doses of catecholamine receptor agonists on exploration in mice. J. Neural. Transm. 37, 229–235 (1976)
Sugerman, A. A.: A pilot study of pimozide in chronic schizophrenia patients. Curr. Ther. Res. 13, 706–713 (1971)
Wode-Helgodt, B., Fyro, B., Gullberg, B., Sedvall, G.: Effect of chlorpromazine treatment on monoamine metabolite levels in cerebrospinal fluid of psychotic patients. Acta Psychiatr. Scand. 56, 129–142 (1977)
Yamamura, H. I., Manian, A. A., Snyder, S. H.: Muscarinic cholinergic receptor binding: Influence of pimozide and chlorpromazine metabolites. Life Sci. 18, 685–692 (1976)
Yaryura-Tobias, J. A., Patito, J. A., Mizrahi, J., Roger, R. V., Cappelletti, S. R.: The action of pimozide on acute psychosis. Acta Psychiatr. Belg. 74, 421–429 (1974)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Post, R.M., Jimerson, D.C., Bunney, W.E. et al. Dopamine and mania: Behavioral and biochemical effects of the dopamine receptor blocker pimozide. Psychopharmacology 67, 297–305 (1980). https://doi.org/10.1007/BF00431272
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00431272